Japan Plasma-Derived Therapeutics Market to Reach US$3.53 Billion by 2033 Strong 6.8% CAGR Driven by Aging Population & Rising Rare Disease Burden Immunoglobulins Lead with Highest 45% Share Key Players Takeda Pharmaceutical, CSL Behring & Grifols

The Japan Plasma-Derived Therapeutics Market is witnessing strong expansion, supported by increasing demand for life-saving biologics, rising prevalence of rare and chronic diseases, and growing reliance on plasma-based products such as immunoglobulins, albumin, and coagulation factors across advanced healthcare systems. The market is further strengthened by Japan's rapidly aging population and continuous advancements in biotechnology-driven plasma fractionation and purification technologies.

The Japan Plasma-Derived Therapeutics Market reached US$1.95 Billion in 2024, rising to US$2.08 Billion in 2025 and is expected to reach US$3.53 Billion by 2033, growing at a CAGR of 6.8% from 2026 to 2033.

Download your exclusive sample report today (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/japan-plasma-derived-therapeutics-market?sindhuri

Growth is strongly driven by the increasing clinical application of plasma-derived therapies in the treatment of immunodeficiency disorders, hemophilia, liver diseases, neurological conditions, and critical care management. Rising awareness of early diagnosis and long-term management of chronic and rare diseases is significantly boosting the demand for immunoglobulin therapies and coagulation factor concentrates across hospitals and specialty clinics in Japan.

Additionally, the expansion of advanced plasma collection infrastructure, improvements in donor screening technologies, and increasing investments in biopharmaceutical manufacturing are playing a crucial role in strengthening domestic supply capabilities. Government support for stable plasma supply chains and stringent regulatory frameworks ensuring product safety and quality are further accelerating market development. Continuous innovation in recombinant and fractionation technologies is also enhancing production efficiency and therapeutic effectiveness.

Japan remains a strategically important market in the Asia-Pacific region, driven by its highly developed healthcare system, strong regulatory oversight, and increasing adoption of high-cost biologics for complex disease management. The country's focus on precision medicine and advanced biologics is expected to further support long-term market growth.

Japan Plasma-Derived Therapeutics Market: Competitive Intelligence
Takeda Pharmaceutical Company, CSL Behring, Grifols S.A., Octapharma AG, and Kedrion Biopharma are among the key global and regional players shaping the competitive landscape of the Japan Plasma-Derived Therapeutics Market. These companies are actively engaged in plasma collection, fractionation, and development of immunoglobulins, albumin, and coagulation factor therapies used across hospitals, specialty care centers, and emergency medicine applications.

The market is primarily driven by the increasing burden of immunological disorders, hemophilia cases, and age-related diseases requiring long-term plasma-based treatment support. Rising healthcare expenditure, along with growing adoption of biologics in clinical practice, is further strengthening market demand across Japan's healthcare ecosystem.

Competitive differentiation in this market is defined by plasma collection capacity, regulatory compliance with Japan's strict pharmaceutical standards, product portfolio diversity, and global supply chain strength. Takeda Pharmaceutical continues to play a dominant role with a strong domestic and international plasma therapy portfolio, while CSL Behring and Grifols maintain leadership in global plasma fractionation and immunoglobulin supply. Strategic priorities among key players include expanding plasma donation networks, increasing production capacity, and advancing next-generation plasma-derived and recombinant therapies.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/japan-plasma-derived-therapeutics-market?sindhuri

Recent Key Developments - Japan Plasma-Derived Therapeutics Market
✅ 2025: Rising demand for immunoglobulins, albumin, and clotting factor concentrates driven by increasing prevalence of immune disorders, hemophilia, and liver diseases across Japan, strengthening plasma fractionation utilization.
✅ May 2025: Expansion of domestic plasma collection and fractionation capacity supported by government-backed initiatives to enhance self-sufficiency in plasma-derived medicinal products and reduce import dependency.
✅ 2025: Growing adoption of advanced purification and viral inactivation technologies improved safety, yield efficiency, and scalability of plasma-derived therapies across Japanese biopharmaceutical manufacturing facilities.

Recent Key Developments - North America & Global Supply Chain Influence
✅ June 2025: Strong demand for immunoglobulin therapies in the United States and Canada influenced global plasma trade flows, indirectly supporting Japan's import diversification strategies and supply agreements.
✅ 2025: Expansion of plasma donation networks and fractionation capacity in North America strengthened global supply availability, supporting Japan's healthcare system through stable plasma-derived product imports.
✅ Early 2026: Strategic collaborations between global plasma fractionation companies and Japanese healthcare stakeholders enhanced technology transfer, supply security, and distribution efficiency for critical plasma therapies.

Recent Key Developments - Product, Technology & Innovation Trends
✅ 2025: Next-generation immunoglobulin formulations with improved purity, extended half-life, and reduced infusion frequency advanced treatment outcomes for chronic immune deficiency and autoimmune disorders in Japan.
✅ 2025: Advanced fractionation and recombinant hybrid technologies improved production efficiency and reduced plasma wastage, supporting higher yield of albumin and coagulation factors.
✅ 2025: Increased focus on pathogen reduction technologies and cold-chain optimization strengthened safety, stability, and regulatory compliance across Japan's plasma-derived therapeutics market.

M&A / Strategic Activity
Recent strategic acquisitions, partnerships, and ecosystem developments shaping the Japan Plasma-Derived Therapeutics Market:

Takeda Pharmaceutical Company Limited - Global plasma leadership expansion
Takeda Pharmaceutical Company Limited continues to strengthen its global plasma-derived therapies portfolio through integration of rare disease pipelines, immunoglobulin therapies, and long-term supply agreements for plasma fractionation, reinforcing its leadership in immunology and hematology treatments.

CSL Behring - Japan plasma supply chain strengthening
CSL Behring has expanded collaborations with Japanese healthcare institutions and plasma collection networks to secure stable immunoglobulin and albumin supply, supporting increasing domestic demand for immune deficiency and critical care therapies.

Grifols - Strategic plasma fractionation partnerships in Asia-Pacific
Grifols has enhanced its presence in Japan through strategic alliances focused on plasma-derived immunoglobulins, albumin, and coagulation factor therapies, supporting growing clinical adoption in neurology and hematology.

Kamada Ltd. - Specialty plasma therapeutics expansion in Japan
Kamada Ltd. has expanded licensing and distribution agreements in Japan for anti-venom and immunoglobulin-based therapies, strengthening niche plasma-derived treatment availability.

Biotest / ADMA Biologics - Supply diversification initiatives
Global plasma companies are increasingly engaging Japanese distributors to diversify supply chains and reduce dependency risks amid rising global demand for plasma-derived medicinal products.

New Product / Therapy Launches & Deployments
Recent innovations and commercial developments in plasma-derived therapeutics in Japan:

Immunoglobulin (IVIG/SCIG) therapy expansion
Major players including Takeda and CSL have expanded next-generation immunoglobulin products targeting primary immunodeficiency, CIDP, and autoimmune neurological disorders, improving dosing flexibility and outpatient administration.

Albumin therapies for critical care and liver disease
Enhanced albumin formulations are increasingly used in Japan for trauma care, liver cirrhosis, and surgical applications, supporting improved plasma volume expansion and patient stabilization in acute care settings.

Coagulation factor concentrates for hemophilia management
Advanced factor VIII and factor IX concentrates are being widely adopted for hemophilia A and B treatment, with improved recombinant-plasma hybrid formulations increasing treatment safety and half-life performance.

Alpha-1 antitrypsin and specialty plasma proteins
Growing use of rare plasma-derived proteins for genetic and chronic conditions, including alpha-1 antitrypsin deficiency therapies, is expanding within Japan's specialty care segment.

Hyperimmune globulins for infectious disease preparedness
Post-pandemic preparedness strategies have accelerated deployment of hyperimmune globulins targeting viral infections and emerging pathogens in clinical and hospital settings.

R&D & Technological Advancements
Recombinant + plasma hybrid therapeutics development
R&D is increasingly focused on combining recombinant technology with plasma-derived proteins to improve consistency, reduce dependency on donor plasma, and enhance safety profiles.

Next-generation fractionation technologies
Advanced plasma fractionation techniques are improving yield efficiency, purity, and scalability of immunoglobulins, albumin, and coagulation factors for large-scale production.

Pathogen reduction and viral inactivation systems
Enhanced safety systems using solvent/detergent and nanofiltration technologies are becoming standard to ensure high viral safety in plasma-derived medicinal products.

Long-acting immunoglobulin formulations
Research is focused on extended half-life IVIG and SCIG formulations, reducing infusion frequency and improving patient compliance in chronic immune disorders.

Personalized immunotherapy approaches
Japan is advancing precision medicine approaches in plasma therapies, tailoring immunoglobulin dosing and treatment regimens based on patient immune profiles and disease severity.

Market Drivers & Emerging Trends
» Rising prevalence of immunodeficiency disorders and autoimmune diseases is significantly increasing demand for immunoglobulin therapies in Japan.
» Aging population is driving higher incidence of neurological, hematological, and chronic inflammatory conditions requiring plasma-derived treatments.
» Expanding hospital infrastructure and advanced clinical care systems are boosting adoption of albumin and coagulation factor therapies.
» Increasing focus on rare disease treatment and orphan drug development is accelerating plasma-derived innovation.
» Strengthened pandemic preparedness strategies are supporting growth of hyperimmune globulin and infectious disease therapies.
» Supply chain security concerns are driving investment in plasma collection networks and global sourcing partnerships.
» Advancements in fractionation and recombinant hybrid technologies are improving scalability and reducing production constraints.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=japan-plasma-derived-therapeutics-market?sindhuri

The Japan Plasma-Derived Therapeutics Market is segmented based on product type, application, end user, source of plasma, and route of administration.
By Product Type
The market is segmented into immunoglobulins (45%), albumin (25%), coagulation factors (20%), and others (10%). Immunoglobulins dominate the segment due to their wide application in treating immune deficiencies, autoimmune diseases, and neurological disorders. Albumin holds a significant share owing to its extensive use in critical care, liver disease management, and surgical procedures. Coagulation factors are increasingly utilized in hemophilia treatment and bleeding disorder management, while other plasma-derived products serve niche therapeutic needs.

By Application
The market is divided into immunology (35%), hematology (30%), neurology (15%), critical care (10%), and others (10%). Immunology leads the segment due to rising prevalence of immune-related disorders and growing use of immunoglobulin therapies. Hematology follows closely with strong demand for treatments targeting bleeding disorders and blood-related conditions. Neurology applications are expanding steadily, particularly for conditions such as chronic inflammatory demyelinating polyneuropathy, while critical care and other applications continue to support hospital-based usage.

By End-User
The market is segmented into hospitals (55%), clinics (20%), blood banks (15%), and research institutes (10%). Hospitals dominate the end-user segment due to high patient inflow and advanced infrastructure for administering plasma-derived therapies. Clinics contribute steadily through outpatient treatments, while blood banks play a key role in plasma collection, storage, and supply chain management. Research institutes support innovation and development of next-generation plasma-derived therapeutics.

By Source of Plasma
The market is divided into domestic plasma (60%) and imported plasma (40%). Domestic plasma holds a larger share due to strong regulatory frameworks, increasing self-sufficiency initiatives, and stable collection networks within Japan. Imported plasma continues to supplement domestic supply to meet growing therapeutic demand and ensure consistent availability of critical products.

By Route of Administration
The market is segmented into intravenous (70%), subcutaneous (25%), and others (5%). Intravenous administration dominates due to its rapid efficacy and widespread use in hospital settings for acute and chronic conditions. Subcutaneous administration is gaining traction for long-term therapy and improved patient convenience, while other routes remain limited to specialized clinical applications.

Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription?sindhuri
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Contact:
Fabian
DataM Intelligence 4market Research LLP 6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology. Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.